Core Insights - There is currently no available vaccine for Chikungunya virus in China, with over 7,000 reported local cases in Guangdong province as of August 9, 2025 [1] - The lack of vaccine development is attributed to limited market potential, high development costs, and competition concerns [2][3] Group 1: Vaccine Development Challenges - The cost of developing a vaccine is significant, with preclinical and early clinical phases costing approximately 30 million yuan each, and late-stage clinical trials potentially exceeding 100 million yuan [2] - The economic value of developing a Chikungunya vaccine is considered limited due to the disease's transmission being reliant on mosquito vectors, which are primarily found in tropical and subtropical regions [2] - The current model of "imported cases leading to local transmission" results in annual incidence numbers that are much lower than more common infectious diseases like influenza and hepatitis B, leading to concerns about market viability for new vaccines [2][3] Group 2: Market and Strategic Considerations - Traditional vaccine development timelines can take five to seven years, during which time the market may be dominated by imported vaccines or emergency imports, creating uncertainty for domestic developers [3] - The clinical trials for vaccines require thousands of participants and must be conducted in tropical and subtropical areas, adding to the complexity and cost of development [3] - Companies are more likely to allocate resources to vaccines with higher return on investment unless there is a clear national strategic reserve need or limitations on imported vaccines [3] Group 3: Prevention Measures - Current prevention strategies focus on mosquito control, including eliminating breeding sites and using repellents and mosquito nets [3]

Core Viewpoint - The company, Keqian Bio (688526), has announced a collaboration with Huazhong Agricultural University to develop four vaccine projects and related testing kits, with a total payment of 4.9 million yuan for the research and development efforts [1] Group 1 - The collaboration includes the development of a combined vaccine for canine diseases and two vaccines for swine diseases, along with an ELISA antibody testing kit for swine [1] - The total payment to Huazhong Agricultural University for the four research projects is 4.9 million yuan [1] - The intellectual property and technological achievements from the collaboration will be jointly owned by both the company and Huazhong Agricultural University [1]

Core Viewpoint - The company, Keqian Bio (688526.SH), has entered into a competitive negotiation with Huazhong Agricultural University to collaborate on the development of four vaccine and testing projects, indicating a strategic move to enhance its product offerings in the veterinary medicine sector [1] Group 1: Collaboration Details - The company will collaborate with Huazhong Agricultural University on the following projects: "Canine Distemper, Canine Parainfluenza, Canine Adenovirus and Canine Parvovirus Quadrivalent Live Vaccine - Inactivated Canine Coronavirus Vaccine," "Inactivated Porcine Gaiter Virus Vaccine," "ELISA Antibody Test Kit for Porcine Proliferative Enteropathy," and "NADC30-like Porcine Reproductive and Respiratory Syndrome Live Vaccine (GX2024 Strain)" [1] - The total payment to Huazhong Agricultural University for these four research and development projects will amount to 4.9 million RMB [1] - The technical achievements and intellectual property generated from the collaboration will be jointly owned by both the company and Huazhong Agricultural University [1]

中慧生物此次全球发行3344.26万股H股，最终发售价为12.90港元，处于发行价格区间的低位，总 募集金额约4.31亿港元。上市所募资金将主要用于其核心产品的开发及国内外注册；其他在研疫苗的开 发和注册；以及改进工艺及商业化能力等方面。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 中慧生物盘初拉升，现涨超12%，报价37.5港元，该股昨日上市飙升158%。 | 02627 中慧生物-B | | | | --- | --- | --- | | 37.500 + +4.220 +12.68% | | 交易中 08/12 09:48 | | 六 2 日 日 中 自选 | | ● 快捷交易 | | 最高价 37.800 | 开盘价 34.000 | 成交量 77.56万 | | 最低价 34.000 | 昨收价 33.280 | 成交额 2772.16万 | | 平均价 35 ...

近段时间，事关基孔肯雅热病毒在我国本土肆虐。 这个消息一经发布之后，导致全球资本市场出现剧变。 甚至出现了由"高利率利差"驱动的资本收割正在新兴市场蔓延。 就在这个时候，中国广东省顺德爆发基孔肯雅热病毒。 而美国却提前五个月就批准研发疫苗。 此次始作俑者居然是所谓的蚊子，而且还没有"特效药"。 事实上，这一切都是美国人干的。 毕竟，美国在基孔肯雅热爆发前，就已经提前研发出疫苗。 再加上美联储此前宣布，将基准利率维持在4.25%至4.5%区间不变。 这是今年以来，美联储连续五次在议息会议之后，宣布基准利率不变。 结果美联储选择按兵不动。 相反，美联储宣布维持现状之后，国际和国内期货市 这就可以视为，美联储拒绝降息，外加生物的双重"绞杀"，也让中美贸易朝着另外一个方向发展。 这件事需要从美联储投下"巨型炸弹"开始说起。 第一，在美联储宣布维持利率之前，主流市场的观点普遍认为，美联储会在无法承受的高利率面前，选 择快速降息。 ...

Industry News - In July 2025, the number of new A-share accounts reached 1.96 million, showing a year-on-year increase of 71% and a month-on-month increase of 19.27% [6] - The China CDC and other teams completed the first phase clinical trial of a copy-type AIDS vaccine using the Tian Tan strain, marking significant progress in AIDS vaccine research in China [6] - The wholesale sales of new energy passenger vehicles in China reached 1.18 million units in July, representing a year-on-year growth of 25% and a cumulative total of 7.63 million units from January to July, up 35% year-on-year [6] - Tencent released four open-source small-sized models suitable for low-power scenarios, which can run on consumer-grade graphics cards [6] Company News - Kweichow Moutai announced a share buyback of 3.45 million shares, with a total payment of 5.301 billion yuan [8] - Leishan Electric announced that starting September 1, residential electricity will be charged at off-peak rates, which is expected to reduce the company's electricity business revenue by approximately 16.6 million yuan in 2025 [9] - Guizhou Moutai's share buyback reflects the company's commitment to enhancing shareholder value [8] - Green通 Technology plans to acquire 51% of DaMo Semiconductor for 530 million yuan, aiming for strategic transformation and industrial upgrade towards the semiconductor industry [10]

Core Viewpoint - The article highlights a significant advancement in HIV vaccine research in China, marking the completion of the first phase of clinical trials for a recombinant HIV vaccine using the Tian Tan strain of vaccinia virus as a carrier, which was previously used to eradicate smallpox [3]. Group 1 - The research was conducted by the Chinese Center for Disease Control and Prevention's AIDS Prevention Center and other teams [3]. - The innovative approach of using the Tian Tan strain of vaccinia virus has been validated for safety and its ability to elicit an effective immune response [3]. - This development signifies an important milestone in the field of HIV vaccine research in China [3].

MACD金叉信号形成，这些股涨势不错！ 据北京日报，中国疾控中心艾防中心等团队完成我国首个复制型天坛痘苗载体艾滋病疫苗I期临床试 验。该研究创新性采用曾用于消灭天花的"天坛株"痘苗病毒为载体，试验验证了该方案的安全性且能激 发有效免疫反应。这标志着我国在艾滋病疫苗研发领域取得重要进展。 受此影响，A股市场生物医药股拉升，其中，南模生物、赛伦生物涨超14%，天坛生物10CM涨停，之 江生物、沃森生物、仁度生物、安旭生物等跟涨。 ...

Core Viewpoint - The completion of the first phase clinical trial of the replication-competent Tian Tan smallpox vaccine vector HIV vaccine marks a significant advancement in HIV vaccine research in China, demonstrating safety and the ability to elicit effective immune responses [1][2]. Group 1: Clinical Trial and Research Progress - The replication-competent Tian Tan smallpox vaccine virus was used as a vector in the study, which has shown safety and the potential to induce durable HIV-specific immune responses in healthy individuals [2]. - The trial involved 48 healthy participants and established a foundation for the upcoming phase II clinical trials [2]. - Despite advancements in antiretroviral therapy and pre-exposure prophylaxis, over one million new HIV infections occur annually, highlighting the ongoing public health challenge posed by HIV [1]. Group 2: Challenges in HIV Vaccine Development - The high variability of the HIV virus and its attack on the immune system present significant challenges for vaccine development [1]. - Over 300 HIV vaccine trials have been conducted globally, with 11 efficacy trials, most of which have failed to demonstrate protective immune effects [1]. - Replication-competent viral vectors, such as adenoviruses and cowpox viruses, are being explored as alternative solutions for HIV antigen delivery [1].

Core Viewpoint - The completion of China's first replicative Tian Tan smallpox vaccine vector HIV vaccine Phase I clinical trial marks a significant advancement in HIV vaccine research in the country [1] Group 1 - The research was conducted by the Chinese Center for Disease Control and Prevention's AIDS Prevention Center and other teams [1] - The innovative approach utilizes the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, as a vector [1] - The trial confirmed the safety of the vaccine and its ability to elicit an effective immune response [1]